|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PAXIP1-AS1 |
Gene summary for PAXIP1-AS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PAXIP1-AS1 | Gene ID | 202781 |
| Gene name | PAXIP1 divergent transcript | |
| Gene Alias | PAXIP1-AS1 | |
| Cytomap | 7q36.2 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 202781 | PAXIP1-AS1 | LZE2T | Human | Esophagus | ESCC | 5.54e-05 | 7.23e-01 | 0.082 |
| 202781 | PAXIP1-AS1 | LZE7T | Human | Esophagus | ESCC | 7.13e-07 | 2.63e-01 | 0.0667 |
| 202781 | PAXIP1-AS1 | LZE24T | Human | Esophagus | ESCC | 1.36e-17 | 4.41e-01 | 0.0596 |
| 202781 | PAXIP1-AS1 | LZE21T | Human | Esophagus | ESCC | 7.20e-03 | 1.52e-01 | 0.0655 |
| 202781 | PAXIP1-AS1 | LZE6T | Human | Esophagus | ESCC | 7.34e-03 | 2.56e-01 | 0.0845 |
| 202781 | PAXIP1-AS1 | P1T-E | Human | Esophagus | ESCC | 6.08e-11 | 3.93e-01 | 0.0875 |
| 202781 | PAXIP1-AS1 | P2T-E | Human | Esophagus | ESCC | 2.21e-05 | 1.24e-01 | 0.1177 |
| 202781 | PAXIP1-AS1 | P4T-E | Human | Esophagus | ESCC | 4.84e-09 | 3.15e-01 | 0.1323 |
| 202781 | PAXIP1-AS1 | P5T-E | Human | Esophagus | ESCC | 1.82e-06 | 1.49e-01 | 0.1327 |
| 202781 | PAXIP1-AS1 | P8T-E | Human | Esophagus | ESCC | 3.21e-22 | 3.48e-01 | 0.0889 |
| 202781 | PAXIP1-AS1 | P9T-E | Human | Esophagus | ESCC | 1.72e-08 | 2.17e-01 | 0.1131 |
| 202781 | PAXIP1-AS1 | P10T-E | Human | Esophagus | ESCC | 7.99e-18 | 3.25e-01 | 0.116 |
| 202781 | PAXIP1-AS1 | P12T-E | Human | Esophagus | ESCC | 1.36e-30 | 6.86e-01 | 0.1122 |
| 202781 | PAXIP1-AS1 | P15T-E | Human | Esophagus | ESCC | 2.07e-19 | 3.70e-01 | 0.1149 |
| 202781 | PAXIP1-AS1 | P16T-E | Human | Esophagus | ESCC | 7.13e-10 | 1.75e-01 | 0.1153 |
| 202781 | PAXIP1-AS1 | P20T-E | Human | Esophagus | ESCC | 5.79e-27 | 6.38e-01 | 0.1124 |
| 202781 | PAXIP1-AS1 | P21T-E | Human | Esophagus | ESCC | 4.36e-22 | 4.52e-01 | 0.1617 |
| 202781 | PAXIP1-AS1 | P22T-E | Human | Esophagus | ESCC | 1.40e-05 | 1.43e-01 | 0.1236 |
| 202781 | PAXIP1-AS1 | P23T-E | Human | Esophagus | ESCC | 3.65e-12 | 3.33e-01 | 0.108 |
| 202781 | PAXIP1-AS1 | P24T-E | Human | Esophagus | ESCC | 5.13e-09 | 1.50e-01 | 0.1287 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |